ACTIVE_NOT_RECRUITING

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Talk to us

Conditions

Progressive Pulmonary FibrosisBMS-986278LPA1 antagonistPulmonary fibrosisInterstitial lung diseaseRheumatoid ArthritisConnective Tissue DisordersSarcoidosisSclerodermaFibrosisAntifibrotic therapy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Official Title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Quick Facts

Study Start:2023-10-25
Study Completion:2027-12-27
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06025578

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

Local Institution - 0046
Birmingham, Alabama, 35294
United States
Local Institution - 0314
Phoenix, Arizona, 85013-4220
United States
Local Institution - 0336
La Jolla, California, 92037-1027
United States
Local Institution - 0212
Los Angeles, California, 90033-5313
United States
Local Institution - 0019
Los Angeles, California, 90095-3075
United States
Local Institution - 0535
Newport Beach, California, 92663-3661
United States
Local Institution - 0366
Orange, California, 92868-3201
United States
Local Institution - 0341
Sacramento, California, 95817
United States
Local Institution - 0015
San Francisco, California, 94143-2202
United States
Local Institution - 0352
Stanford, California, 94305
United States
Local Institution - 0321
Aurora, Colorado, 80045
United States
Local Institution - 0376
Denver, Colorado, 80206
United States
Local Institution - 0211
New Haven, Connecticut, 06510
United States
Local Institution - 0418
Stamford, Connecticut, 06904
United States
Local Institution - 0067
Newark, Delaware, 19713-1337
United States
Local Institution - 0354
Washington D.C., District of Columbia, 20007-2113
United States
Local Institution - 0195
Brandon, Florida, 33511-5706
United States
Local Institution - 0380
Celebration, Florida, 34747-1818
United States
Local Institution - 0013
Clearwater, Florida, 33765
United States
Local Institution - 0396
DeBary, Florida, 32713-1817
United States
Local Institution - 0036
Gainesville, Florida, 32608
United States
Local Institution - 0193
Gainesville, Florida, 32610
United States
Local Institution - 0073
Loxahatchee Groves, Florida, 33411
United States
Local Institution - 0220
Ocala, Florida, 34470
United States
Local Institution - 0452
Pensacola, Florida, 32503
United States
Local Institution - 0389
St. Petersburg, Florida, 33704
United States
Local Institution - 0316
Tampa, Florida, 33601-1289
United States
Local Institution - 0070
Atlanta, Georgia, 30322-1013
United States
Local Institution - 0368
Dublin, Georgia, 31021-2561
United States
Local Institution - 0435
Chicago, Illinois, 60611
United States
Local Institution - 0023
Chicago, Illinois, 60637-1447
United States
Local Institution - 0040
Evanston, Illinois, 60201-1779
United States
Local Institution - 0082
Maywood, Illinois, 60153-3328
United States
Local Institution - 0080
Iowa City, Iowa, 522242-1009
United States
Local Institution - 0049
Kansas City, Kansas, 66103-2937
United States
Local Institution - 0045
Louisville, Kentucky, 40207-4652
United States
Local Institution - 0361
Louisville, Kentucky, 40218-2497
United States
Local Institution - 0305
Baltimore, Maryland, 21201-1544
United States
Local Institution - 0033
Towson, Maryland, 21204-7700
United States
Local Institution - 0404
Boston, Massachusetts, 02114-2621
United States
Local Institution - 0079
Springfield, Massachusetts, 01199-1002
United States
Local Institution - 0207
Ann Arbor, Michigan, 48109-5000
United States
Local Institution - 0031
Detroit, Michigan, 48202
United States
Local Institution - 0050
Grand Rapids, Michigan, 49546-8293
United States
Local Institution - 0509
Royal Oak, Michigan, 48073-6712
United States
Local Institution - 0384
Minneapolis, Minnesota, 55455-4800
United States
Local Institution - 0004
Chesterfield, Missouri, 63017
United States
Local Institution - 0223
St Louis, Missouri, 63110-1010
United States
Local Institution - 0525
Reno, Nevada, 89502-1576
United States
Local Institution - 0068
Mount Kisco, New York, 10549-3417
United States
Local Institution - 0357
New York, New York, 10029-6574
United States
Local Institution - 0428
Durham, North Carolina, 27710
United States
Local Institution - 0392
Wilmington, North Carolina, 28401-7307
United States
Local Institution - 0325
Winston-Salem, North Carolina, 27103
United States
Local Institution - 0419
Cincinnati, Ohio, 45267
United States
Local Institution - 0186
Cleveland, Ohio, 44106
United States
Local Institution - 0209
Columbus, Ohio, 43201
United States
Local Institution - 0343
Toledo, Ohio, 43608-2603
United States
Local Institution - 0198
Oklahoma City, Oklahoma, 73104-5417
United States
Local Institution - 0008
Tulsa, Oklahoma, 74133
United States
Local Institution - 0037
Portland, Oregon, 97239-3011
United States
Local Institution - 0205
Hershey, Pennsylvania, 17033-2360
United States
Local Institution - 0334
Philadelphia, Pennsylvania, 19104-5161
United States
Local Institution - 0348
Philadelphia, Pennsylvania, 19107-5109
United States
Local Institution - 0196
Philadelphia, Pennsylvania, 19140-5103
United States
Local Institution - 0364
Wynnewood, Pennsylvania, 19096
United States
Local Institution - 0531
Anderson, South Carolina, 29621
United States
Local Institution - 0071
Charleston, South Carolina, 29425
United States
Local Institution - 0373
Greenville, South Carolina, 29615
United States
Local Institution - 0363
Nashville, Tennessee, 37204
United States
Local Institution - 0024
Dallas, Texas, 75235-5351
United States
Local Institution - 0317
Dallas, Texas, 75246
United States
Local Institution - 0028
Houston, Texas, 77030-4202
United States
Local Institution - 0041
Houston, Texas, 77030
United States
Local Institution - 0221
McKinney, Texas, 75069
United States
Local Institution - 0217
San Antonio, Texas, 78229-4404
United States
Local Institution - 0014
Salt Lake City, Utah, 84108
United States
Local Institution - 0504
Burlington, Vermont, 05401
United States
Local Institution - 0414
Richmond, Virginia, 23298-5002
United States
Local Institution - 0190
Everett, Washington, 98208-6526
United States
Local Institution - 0043
Seattle, Washington, 98195
United States

Collaborators and Investigators

Sponsor: Bristol-Myers Squibb

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-25
Study Completion Date2027-12-27

Study Record Updates

Study Start Date2023-10-25
Study Completion Date2027-12-27

Terms related to this study

Keywords Provided by Researchers

  • BMS-986278
  • LPA1 antagonist
  • Pulmonary fibrosis
  • Interstitial lung disease
  • Rheumatoid Arthritis
  • Connective Tissue Disorders
  • Sarcoidosis
  • Scleroderma
  • Fibrosis
  • Antifibrotic therapy

Additional Relevant MeSH Terms

  • Progressive Pulmonary Fibrosis